CD2-HM12NB-100μg / 询价
CD2-HM12NB-100μgx5 / 询价
CD2-HM12NB-100μgx10 / 询价
- 关联产品
- 客服电话
- 技术支持
Biotinylated Human CD20/MS4A1 Nanodisc
Recombinant Biotinylated Human CD20/MS4A1 Nanodisc is expressed from HEK293 with His tag at the C-terminus.It contains Met1-Pro297 [Accession | P11836-1].
The protein has a predicted MW of 46.0 kDa.
Less than 1 EU per μg by the LAL method.
Supplied as 0.22 μm filtered solution in PBS, 200mM L-Arginine (pH 7.4). Notice: Not recommended for flow cytometry in mammalian cells.
Valid for 6 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Immobilized Biotinylated Human CD20 Nanodisc, His Tag at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Ofatumumab, hFc Tag with the EC50 of 30.8ng/ml determined by ELISA. (QC Test)
Immobilized Biotinylated Human CD20 Nanodisc, His Tag at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Rituximab, hFc Tag with the EC50 of 0.16μg/ml determined by ELISA.
Immobilized Biotinylated Human CD20 Nanodisc, His Tag at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Obinutuzumab, hFc Tag with the EC50 of 7.9ng/ml determined by ELISA.
Biotinylated Human CD20 Nanodisc captured on CM5 Chip via Streptavidin can bind Rituximab, hFc Tag with an affinity constant of 10.21 nM as determined in SPR assay (Biacore T200).
Loaded Biotinylated Human CD20 Nanodisc, His Tag on Streptavidin-Biosensor can bind Rituximab, hFc Tag with an affinity constant of 6.94 nM as determined in BLI assay (Gator® Prime).
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
MS4A1; CD20; MS4A-1; B1; Bp35; CD20 receptor; CD20S7; CVID5; LEU-16; Ly-44; MS4A2; S7
(1)Ma D , Mcdevitt M R , Barendswaard E , et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies[J]. Leukemia, 2002, 16(1):60-66.
(2)Jager U , Fridrik M , Zeitlinger M , et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response[J]. Haematologica, 2012, 97(9):1431-1438.
